Receive our newsletter – data, insights and analysis delivered to you

China accounts for 24.7% share of global clinical trial activity in 2020

China has accounted for a 24.7% share of the global clinical trials activity in 2020, registering an increase when compared with the last ten-year average of a 12.0% share, according to GlobalData.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Non-Industry sponsored trials outnumber industry sponsored trials in China

Industry sponsored trials held a 47.3% share of all the clinical trials in China in 2020, when compared with the ten-year average of 36.6%. Non-industry sponsored trials accounted for a 52.7% share in 2020 as against the average of 63.4% in the last ten years.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top therapy areas for industry sponsored clinical trials in China

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

Oncology was the leading therapy area for industry sponsored clinical trials in China in 2020 with a 33.9% share, as against a five-year average of 36.0% and a ten-year average of 33.1%.

Infectious Disease held an 18.3% share in 2020, over a five-year average of 12.7% and a ten-year average of 13.4%.

Respiratory held an 11.3% share in 2020, compared to a five-year average of 7.3% and a ten-year average of 6.2%. Cardiovascular held a 10.6% share in 2020, as against a five-year average of 12.6% and a ten-year average of 12.8%.

Central Nervous System held a 10.1% share, over a five-year average of 9.8% and a ten-year average of 9.9%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top therapy areas for non-industry sponsored clinical trials in China

Oncology was the leading therapy area for non-industry sponsored clinical trials in China in 2020 with a 39.5% share, as against a five-year average of 35.0% and a ten-year average of 33.1%.

Central Nervous System held a 14.6% share in 2020, over a five-year average of 17.5% and a ten-year average of 16.0%.

Infectious Disease held a 14.5% share in 2020, compared to a five-year average of 7.4% and a ten-year average of 8.9%. Respiratory held an 11.8% share in 2020, as against a five-year average of 4.0% and a ten-year average of 4.6%.

Cardiovascular held an 8.8% share, over a five-year average of 11.6% and a ten-year average of 12.6%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Phase I trials lead industry sponsored clinical trials in China in 2020

Phase I trials held a 55.3% share of industry sponsored clinical trials in China in 2020, over a five-year average of 46.4% and a ten-year average of 31.0%.

Phase II trials held a 21.8% share in 2020, as against a five-year average of 20.4% and a ten-year average of 20.2%. Phase III trials held a 12.5% share in 2020, compared to a five-year average of 18.2% and a ten-year average of 26.7%.

Phase IV trials held a 10.3% share in 2020, over a five-year average of 14.9% and a ten-year average of 22.0%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Phase I trials lead non-industry sponsored clinical trials in China in 2020

Phase I trials held a 35.0% share of non-industry sponsored clinical trials in China in 2020, over a five-year average of 12.2% and a ten-year average of 10.6%.

Phase II trials held a 33.5% share in 2020, as against a five-year average of 50.8% and a ten-year average of 48.1%. Phase IV trials held a 25.4% share, compared to a five-year average of 28.2% and a ten-year average of 30.1%.

Phase III held a 6.1% share in 2020, over a five-year average of 8.8% and a ten-year average of 11.1%.

  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Methodology:

The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU